| Formulation |
Pharmacokinetic parameters |
Reference |
| Tmax |
Cmax |
Cmax/Dose |
AUC0-t |
AUC0-t/Dose |
AUC0-∞ |
AUC0-∞/Dose |
T1/2 |
| (Hours) |
(ng/mL) |
(ng/mg ml) |
(ng.hr/m) |
(ng.hr/ mg. mL) |
(ng.hr/mL) |
(ng.hr/mg. mL) |
(Hours) |
| Vastarel 20 mg (SD) |
2.7 ± 1 |
47 ± 9 |
2.35 |
369.8 ± 76 |
18.49 |
789.6 ± 165 |
39.48 |
4.6 ± 1.3 |
[27] |
| IR 20 mg |
2.0 ± 0.008 |
35.0 ± 5.2 |
1.75 |
- |
- |
623.8 ± 100.8 |
31.19 |
7.39 ± 1.1 |
[30] |
| IR 20 mg |
1.8 |
53.6 |
2.68 |
- |
- |
508.9 |
25.445 |
6 |
[31] |
| IR 40 mg |
2.73 |
127.5 |
3.1875 |
- |
- |
- |
- |
- |
| Test 20 mg |
2.312 ± 0.66 |
74.85 ± 12.13 |
3.7425 |
673.1 ± 117.6 |
33.655 |
717.1 ± 120.9 |
35.855 |
4.78 ± 0.92 |
[32] |
| Reference 20 mg |
2.211 ± 0.61 |
71.93 ± 14.32 |
3.5965 |
652.3 ± 121.9 |
32.615 |
692 ± 128.6 |
34.6 |
4.74 ± 0.82 |
| Reference 35 mg MR |
3.54 |
98.57 |
2.82 |
410.01
(t-12) |
|
462.78 |
13.22 |
3.45 |
[33] |
| Test 35 mg MR (Metacard) |
4 |
104.78 |
2.99 |
423.81 |
12.11 |
472.51 |
13.50 |
3.69 |
| Test 35 mg MR (Matenol) (Fasting Study) |
5 |
142 |
4.06 |
1320 |
37.71 |
1430 |
40.86 |
5.62 |
[34] |
| Vastarel 35 mg MR (Fasting Study) |
4.5 |
135 |
3.86 |
1270 |
36.29 |
1360 |
38.86 |
5.32 |
Test 35 mg MR (Matenol)
(Fed Study) |
4.5 |
183 |
5.23 |
1440 |
41.14 |
1530 |
43.71 |
4.97 |
| Vastarel 35 mg MR (Fed Study) |
5 |
169 |
4.83 |
1450 |
41.43 |
1580 |
45.14 |
5.29 |
| Three layer matrix tablet 50 mg |
6.1 ± 0.6 |
61.5 ± 3.3 |
1.23 |
- |
|
1327.9 ± 304.5 |
26.56 |
20.84 ± 3.0 |
[30] |
| Test 70 mg (OD) |
6 |
85.443 |
1.22 |
1656.903 |
23.66 |
- |
- |
7.29 |
In-House Study |
| Preductal 35 mg MR |
4.5 |
69.366 |
1.98 |
592.56 |
16.93 |
- |
- |
5.25 |
